Cargando…
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic chemotherapy that provided a response rate of 20–35 % and a median survival time (MST) of 10–12 months. In 2004, it was found that activated mutations of the epidermal growth factor receptor (EGFR) gene were p...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591525/ https://www.ncbi.nlm.nih.gov/pubmed/23361373 http://dx.doi.org/10.1007/s11523-013-0258-9 |